Nanoform

Nanoform Finland Oyj was founded in 2015 in Helsinki, Finland as a spin-out from the University of Helsinki, where founders Prof. Jouko Yliruusi and Prof. Edward Haeggstrom discovered the underlying particle engineering process in 2012. The company addresses poor solubility and bioavailability, a common reason drug candidates fail or require high doses.

Its CESS (Controlled Expansion of Supercritical Solutions) technology produces nanoformed active ingredient particles, allowing higher drug loads in smaller tablets, in subcutaneous injections and in alternative delivery formats such as inhalation. STARMAP, an AI-based online tool, assesses whether a molecule is suitable for nanoforming before laboratory work starts. Nanoform sells particle engineering, formulation and analytical services plus GMP manufacturing at clinical and commercial scale to pharmaceutical and biotech companies, covering both small molecules and biologics. The company listed on Nasdaq First North Premier in 2020 and in August 2026 reported positive UK MHRA regulatory feedback on nanoenzalutamide.

1. CESS technology: supercritical process producing nanoformed API particles, discovered at the University of Helsinki in 2012.

2. STARMAP: AI-based online tool that scores a molecule's suitability for nanoforming before laboratory work begins.

3. Delivery formats: enables higher drug loads in smaller tablets, subcutaneous injections and inhaled routes.

4. Biologics: formulation work extends beyond small molecules to proteins and peptides.

5. GMP manufacturing: clinical and commercial scale production alongside formulation and analytical services.

6. Regulatory progress: positive MHRA feedback on nanoenzalutamide reported in August 2026; listed on Nasdaq First North Premier since 2020.